EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSCPOG00000000431
Gene Symbol: PSMD1
2 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSCPOG00000009798
Gene Symbol: PSMD11
2 Cross references
283 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSCPOG00000004023
Gene Symbol: PSMD12
4 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSCPOG00000003592
Gene Symbol: PSMD13
2 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSCPOG00000005879
Gene Symbol: PSMD14
2 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSCPOG00000006160
Gene Symbol: PSMD6
2 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSCPOG00000011098
Gene Symbol: PSMD7
2 Cross references
242 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSCPOG00000011009
Gene Symbol: PSMD8
4 Cross references
209 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSCPOG00000014048
Gene Symbol: PSMB11
4 Cross references
228 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSCPOG00000014038
Gene Symbol: PRMT5
4 Cross references
199 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSCPOG00000014901
Gene Symbol: PRKCA
2 Cross references
213 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSCPOG00000003455
Gene Symbol: PRKCB
2 Cross references
299 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).